To explore whether alternative targeting of the DNA damage response by inhibiting MDM2 could also be synergistic with KDM6B inhibition, we treated five different neuroblastoma cell lines with the combination of GSK-J4 and Nutlin-3. The gene discussed is KDM6B; the disease is neuroblastoma.